Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.77
-0.03-0.25%
At close: -
$11.77
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Comments
Loading...
Sotera Health Analyst Ratings and Price Targets | NASDAQ:SHC | Benzinga
Sotera Health Co has a consensus price target of $16.45 based on the ratings of 11 analysts. The high is $25 issued by Wolfe Research on January 11, 2023. The low is $8 issued by Goldman Sachs on November 23, 2022. The 3 most-recent analyst ratings were released by Barclays, Barclays, and RBC Capital on February 28, 2025, February 18, 2025, and November 21, 2024, respectively. With an average price target of $16.67 between Barclays, Barclays, and RBC Capital, there's an implied 41.60% upside for Sotera Health Co from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
RBC Capital
Citigroup
Piper Sandler
Jefferies
1calculated from analyst ratings
Analyst Ratings for Sotera Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/28/2025 | Buy Now | 35.94% | Barclays | Luke Sergott51% | $17 → $16 | Maintains | Overweight | Get Alert |
| 02/18/2025 | Buy Now | 44.44% | Barclays | Luke Sergott51% | $18 → $17 | Maintains | Overweight | Get Alert |
| 11/21/2024 | Buy Now | 44.44% | RBC Capital | Sean Dodge49% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 11/06/2024 | Buy Now | 69.92% | Citigroup | Patrick Donnelly80% | $18 → $20 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 44.44% | Barclays | Luke Sergott51% | $14 → $17 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 44.44% | RBC Capital | Sean Dodge49% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/21/2024 | Buy Now | 10.45% | Piper Sandler | Jason Bednar54% | → $13 | Initiates | → Neutral | Get Alert |
| 04/10/2024 | Buy Now | 18.95% | Barclays | Luke Sergott51% | $19 → $14 | Maintains | Overweight | Get Alert |
| 04/03/2024 | Buy Now | 35.94% | Citigroup | Patrick Donnelly80% | $18 → $16 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | Buy Now | 31.69% | Jefferies | David Windley74% | $15 → $15.5 | Upgrade | Hold → Buy | Get Alert |
| 03/11/2024 | Buy Now | 69.92% | RBC Capital | Sean Dodge49% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/04/2024 | Buy Now | 69.92% | RBC Capital | Sean Dodge49% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 61.43% | Barclays | Luke Sergott51% | $17 → $19 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | — | Keybanc | Brett Fishbin52% | — | Initiates | → Sector Weight | Get Alert |
| 01/25/2024 | Buy Now | 44.44% | Barclays | Luke Sergott51% | $15 → $17 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 69.92% | RBC Capital | Sean Dodge49% | $22 → $20 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 27.44% | Barclays | Luke Sergott51% | $20 → $15 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 86.92% | RBC Capital | Sean Dodge49% | $18 → $22 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 95.41% | Keybanc | Matthew Mishan53% | $24 → $23 | Maintains | Overweight | Get Alert |
| 06/26/2023 | Buy Now | 103.91% | Keybanc | Matthew Mishan53% | → $24 | Upgrade | Sector Weight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | — | Keybanc | Matthew Mishan53% | — | Maintains | Sector Weight | Get Alert |
| 05/04/2023 | Buy Now | 52.93% | RBC Capital | Sean Dodge49% | $19 → $18 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 69.92% | Barclays | Luke Sergott51% | $21 → $20 | Maintains | Overweight | Get Alert |
| 04/04/2023 | Buy Now | 78.42% | Barclays | Luke Sergott51% | $22 → $21 | Maintains | Overweight | Get Alert |
| 03/01/2023 | Buy Now | 61.43% | RBC Capital | Sean Dodge49% | $8 → $19 | Maintains | Outperform | Get Alert |
| 01/23/2023 | Buy Now | 52.93% | JP Morgan | Casey Woodring27% | $6 → $18 | Upgrade | Underweight → Neutral | Get Alert |
| 01/11/2023 | Buy Now | 86.92% | Barclays | Luke Sergott51% | $6 → $22 | Upgrade | Underweight → Overweight | Get Alert |
| 01/11/2023 | Buy Now | 112.4% | Wolfe Research | Mike Polark55% | → $25 | Upgrade | Peer Perform → Outperform | Get Alert |
| 11/23/2022 | Buy Now | -32.03% | Goldman Sachs | Amit Hazan56% | $9 → $8 | Maintains | Neutral | Get Alert |
| 11/16/2022 | Buy Now | -49.02% | Barclays | Luke Sergott51% | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/15/2022 | Buy Now | -49.02% | Barclays | Luke Sergott51% | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/03/2022 | Buy Now | -49.02% | JP Morgan | Casey Woodring27% | $9 → $6 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | -32.03% | RBC Capital | Sean Dodge49% | $25 → $8 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | -32.03% | Barclays | Luke Sergott51% | $22 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/05/2022 | Buy Now | -23.53% | Citigroup | Patrick Donnelly80% | → $9 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2022 | Buy Now | — | Keybanc | Matthew Mishan53% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 09/21/2022 | Buy Now | -23.53% | JP Morgan | Tycho Peterson82% | $26 → $9 | Downgrade | Overweight → Underweight | Get Alert |
| 09/20/2022 | Buy Now | -23.53% | Goldman Sachs | Amit Hazan56% | $23 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 07/13/2022 | Buy Now | 86.92% | Barclays | Luke Sergott51% | $24 → $22 | Maintains | Equal-Weight | Get Alert |
| 06/09/2022 | Buy Now | 120.9% | Wolfe Research | Mike Polark55% | → $26 | Downgrade | Outperform → Peer Perform | Get Alert |
| 04/06/2022 | Buy Now | 120.9% | Wolfe Research | Mike Polark55% | → $26 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Sotera Health (SHC) stock?
The latest price target for Sotera Health (NASDAQ:SHC) was reported by Barclays on February 28, 2025. The analyst firm set a price target for $16.00 expecting SHC to rise to within 12 months (a possible 35.94% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sotera Health (SHC)?
The latest analyst rating for Sotera Health (NASDAQ:SHC) was provided by Barclays, and Sotera Health maintained their overweight rating.
When was the last upgrade for Sotera Health (SHC)?
The last upgrade for Sotera Health Co happened on April 3, 2024 when Citigroup raised their price target to $16. Citigroup previously had a neutral for Sotera Health Co.
When was the last downgrade for Sotera Health (SHC)?
The last downgrade for Sotera Health Co happened on November 16, 2022 when Barclays changed their price target from $7 to $6 for Sotera Health Co.
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.
Is the Analyst Rating Sotera Health (SHC) correct?
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $17.00 to $16.00. The current price Sotera Health (SHC) is trading at is $11.77, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.